Biotech Values

[mcbio]

EPIX - 9/17 slide deck

http://www.essapharma.com/wp-content/uploads/2017/09/ESSA_Rodman-Slide-Deck_090917_FINAL.pdf

Here's the aforementioned slide deck. Big question for me is whether or not the limitations of the first-gen NTD inhibitor (EPI-506) for mCRPC were truly due to lack of potency, bioavailability, etc. or is it simply due to the target itself?